全文获取类型
收费全文 | 2710篇 |
免费 | 260篇 |
专业分类
2970篇 |
出版年
2022年 | 28篇 |
2021年 | 48篇 |
2020年 | 22篇 |
2019年 | 37篇 |
2018年 | 45篇 |
2017年 | 32篇 |
2016年 | 69篇 |
2015年 | 123篇 |
2014年 | 124篇 |
2013年 | 165篇 |
2012年 | 157篇 |
2011年 | 198篇 |
2010年 | 118篇 |
2009年 | 105篇 |
2008年 | 138篇 |
2007年 | 198篇 |
2006年 | 176篇 |
2005年 | 159篇 |
2004年 | 131篇 |
2003年 | 131篇 |
2002年 | 156篇 |
2001年 | 27篇 |
2000年 | 17篇 |
1999年 | 29篇 |
1998年 | 37篇 |
1997年 | 27篇 |
1996年 | 24篇 |
1995年 | 27篇 |
1994年 | 21篇 |
1993年 | 32篇 |
1992年 | 20篇 |
1991年 | 20篇 |
1990年 | 17篇 |
1989年 | 17篇 |
1988年 | 24篇 |
1987年 | 21篇 |
1986年 | 22篇 |
1985年 | 18篇 |
1984年 | 16篇 |
1983年 | 8篇 |
1982年 | 9篇 |
1981年 | 16篇 |
1980年 | 23篇 |
1979年 | 10篇 |
1978年 | 15篇 |
1975年 | 14篇 |
1973年 | 13篇 |
1972年 | 10篇 |
1971年 | 12篇 |
1969年 | 8篇 |
排序方式: 共有2970条查询结果,搜索用时 15 毫秒
91.
Peter W. Glunz Xiaojun Zhang Yan Zou Indawati Delucca Alexandra H. Nirschl Xuhong Cheng Carolyn A. Weigelt Daniel L. Cheney Anzhi Wei Rushith Anumula Joseph M. Luettgen Alan R. Rendina Mark Harpel Gang Luo Robert Knabb Pancras C. Wong Ruth R. Wexler E. Scott Priestley 《Bioorganic & medicinal chemistry letters》2013,23(18):5244-5248
Aminoisoquinoline and isoquinoline groups have successfully replaced the more basic P1 benzamidine group of an acylsulfonamide factor VIIa inhibitor. Inhibitory activity was optimized by the identification of additional hydrophobic and hydrophilic P′ binding interactions. The molecular details of these interactions were elucidated by X-ray crystallography and molecular modeling. We also show that decreasing the basicity of the P1 group results in improved oral bioavailability in this chemotype. 相似文献
92.
John N. Freskos Bethel Asmelash Kimberly R. Gaston Amol Karwa Tim A. Marzan Maureen A. Nickols Thomas E. Rogers Tasha Schoenstein Carolyn J. Sympson Bich Vu 《Bioorganic & medicinal chemistry letters》2013,23(20):5566-5570
We describe the synthesis, MMP-2 and 9 potency, and in vitro evaluation of a series of α-sulfone hydroxmate MMP inhibitors conjugated to a series of dyes with different absorption/emission lamina maxima’s that can be used to visualize tumors. 相似文献
93.
Calliandra B. Harris Winyoo Chowanadisai Darya O. Mishchuk Mike A. Satre Carolyn M. Slupsky Robert B. Rucker 《The Journal of nutritional biochemistry》2013,24(12):2076-2084
Pyrroloquinoline quinone (PQQ) influences energy-related metabolism and neurologic functions in animals. The mechanism of action involves interactions with cell signaling pathways and mitochondrial function. However, little is known about the response to PQQ in humans. Using a crossover study design, 10 subjects (5 females, 5 males) ingested PQQ added to a fruit-flavored drink in two separate studies. In study 1, PQQ was given in a single dose (0.2 mg PQQ/kg). Multiple measurements of plasma and urine PQQ levels and changes in antioxidant potential [based on total peroxyl radical-trapping potential and thiobarbituric acid reactive product (TBAR) assays] were made throughout the period of 48 h. In study 2, PQQ was administered as a daily dose (0.3 mg PQQ/kg). After 76 h, measurements included indices of inflammation [plasma C-reactive protein, interleukin (IL)-6 levels], standard clinical indices (e.g., cholesterol, glucose, high-density lipoprotein, low-density lipoprotein, triglycerides, etc.) and 1H-nuclear magnetic resonance estimates of urinary metabolites related in part to oxidative metabolism. The standard clinical indices were normal and not altered by PQQ supplementation. However, dietary PQQ exposure (Study 1) resulted in apparent changes in antioxidant potential based on malonaldehyde-related TBAR assessments. In Study 2, PQQ supplementation resulted in significant decreases in the levels of plasma C-reactive protein, IL-6 and urinary methylated amines such as trimethylamine N-oxide, and changes in urinary metabolites consistent with enhanced mitochondria-related functions. The data are among the first to link systemic effects of PQQ in animals to corresponding effects in humans. 相似文献
94.
95.
Daria Grafodatskaya Barian HY Chung Darci T Butcher Andrei L Turinsky Sarah J Goodman Sana Choufani Yi-An Chen Youliang Lou Chunhua Zhao Rageen Rajendram Fatima E Abidi Cindy Skinner James Stavropoulos Carolyn A Bondy Jill Hamilton Shoshana Wodak Stephen W Scherer Charles E Schwartz Rosanna Weksberg 《BMC medical genomics》2013,6(1):1-18
Background
A number of neurodevelopmental syndromes are caused by mutations in genes encoding proteins that normally function in epigenetic regulation. Identification of epigenetic alterations occurring in these disorders could shed light on molecular pathways relevant to neurodevelopment.Results
Using a genome-wide approach, we identified genes with significant loss of DNA methylation in blood of males with intellectual disability and mutations in the X-linked KDM5C gene, encoding a histone H3 lysine 4 demethylase, in comparison to age/sex matched controls. Loss of DNA methylation in such individuals is consistent with known interactions between DNA methylation and H3 lysine 4 methylation. Further, loss of DNA methylation at the promoters of the three top candidate genes FBXL5, SCMH1, CACYBP was not observed in more than 900 population controls. We also found that DNA methylation at these three genes in blood correlated with dosage of KDM5C and its Y-linked homologue KDM5D. In addition, parallel sex-specific DNA methylation profiles in brain samples from control males and females were observed at FBXL5 and CACYBP.Conclusions
We have, for the first time, identified epigenetic alterations in patient samples carrying a mutation in a gene involved in the regulation of histone modifications. These data support the concept that DNA methylation and H3 lysine 4 methylation are functionally interdependent. The data provide new insights into the molecular pathogenesis of intellectual disability. Further, our data suggest that some DNA methylation marks identified in blood can serve as biomarkers of epigenetic status in the brain. 相似文献96.
Freddy Sitas Alison Gibberd Clare Kahn Marianne F. Weber May Chiew Rajah Supramaniam Louiza Velentzis Carolyn Nickson David P. Smith Dianne O’Connell Megan A. Smith Katie Armstrong Xue Qin Yu Karen Canfell Monica Robotin Eleonora Feletto Andrew Penman 《Cancer epidemiology》2013,37(6):780-787
BackgroundAustralia has one of the highest rates of cancer incidence worldwide and, despite improving survival, cancer continues to be a major public health problem. Our aim was to provide simple summary measures of changes in cancer mortality and incidence in Australia so that progress and areas for improvement in cancer control can be identified.MethodsWe used national data on cancer deaths and newly registered cancer cases and compared expected and observed numbers of deaths and cases diagnosed in 2007. The expected numbers were obtained by applying 1987 age–sex specific rates (average of 1986–1988) directly to the 2007 population. The observed numbers of deaths and incident cases were calculated for 2007 (average of 2006–2008). We limited the analyses to people aged less than 75 years.ResultsThere was a 28% fall in cancer mortality (7827 fewer deaths in 2007 vs. 1987) and a 21% increase in new cancer diagnoses (13,012 more diagnosed cases in 2007). The greatest reductions in deaths were for cancers of the lung in males (?2259), bowel (?1797), breast (?773) and stomach (?577). Other notable falls were for cancers of the prostate (?295), cervix (?242) and non-Hodgkin lymphoma (?240). Only small or no changes occurred in mortality for cancers of the lung (female only), pancreas, brain and related, oesophagus and thyroid, with an increase in liver cancer (267). Cancer types that showed the greatest increase in incident cases were cancers of the prostate (10,245), breast (2736), other cancers (1353), melanoma (1138) and thyroid (1107), while falls were seen for cancers of the lung (?1705), bladder (?1110) and unknown primary (?904).ConclusionsThe reduction in mortality indicates that prevention strategies, improvements in cancer treatment, and screening programmes have made significant contributions to cancer control in Australia since 1987. The rise in incidence is partly due to diagnoses being brought forward by technological improvements and increased coverage of screening and early diagnostic testing. 相似文献
97.
98.
Jiandong Zheng Xixiang Huo Yang Huai Lin Xiao Hui Jiang John Klena Carolyn M. Greene Xuesen Xing Jigui Huang Shali Liu Youxing Peng Hui Yang Jun Luo Zhibin Peng Linlin Liu Maoyi Chen Hui Chen Yuzhi Zhang Danqin Huang Xuhua Guan Luzhao Feng Faxian Zhan Dale J. Hu Jay K. Varma Hongjie Yu 《PloS one》2016,11(3)
99.
Andrés B. Lantos Giannina Carlevaro Beatriz Araoz Pablo Ruiz Diaz María de los Milagros Camara Carlos A. Buscaglia Mariano Bossi Hai Yu Xi Chen Carolyn R. Bertozzi Juan Mucci Oscar Campetella 《PLoS pathogens》2016,12(4)
Trypanosoma cruzi, the flagellate protozoan agent of Chagas disease or American trypanosomiasis, is unable to synthesize sialic acids de novo. Mucins and trans-sialidase (TS) are substrate and enzyme, respectively, of the glycobiological system that scavenges sialic acid from the host in a crucial interplay for T. cruzi life cycle. The acquisition of the sialyl residue allows the parasite to avoid lysis by serum factors and to interact with the host cell. A major drawback to studying the sialylation kinetics and turnover of the trypomastigote glycoconjugates is the difficulty to identify and follow the recently acquired sialyl residues. To tackle this issue, we followed an unnatural sugar approach as bioorthogonal chemical reporters, where the use of azidosialyl residues allowed identifying the acquired sugar. Advanced microscopy techniques, together with biochemical methods, were used to study the trypomastigote membrane from its glycobiological perspective. Main sialyl acceptors were identified as mucins by biochemical procedures and protein markers. Together with determining their shedding and turnover rates, we also report that several membrane proteins, including TS and its substrates, both glycosylphosphatidylinositol-anchored proteins, are separately distributed on parasite surface and contained in different and highly stable membrane microdomains. Notably, labeling for α(1,3)Galactosyl residues only partially colocalize with sialylated mucins, indicating that two species of glycosylated mucins do exist, which are segregated at the parasite surface. Moreover, sialylated mucins were included in lipid-raft-domains, whereas TS molecules are not. The location of the surface-anchored TS resulted too far off as to be capable to sialylate mucins, a role played by the shed TS instead. Phosphatidylinositol-phospholipase-C activity is actually not present in trypomastigotes. Therefore, shedding of TS occurs via microvesicles instead of as a fully soluble form. 相似文献
100.